MCE 的所有產(chǎn)品僅用作科學研究或藥證申報，我們不為任何個人用途提供產(chǎn)品和服務,。

Elsubrutinib

CAS No. : 1643570-24-4

產(chǎn)品活性：Elsubrutinib (ABBV-105) is an orally active, potent, selective and irreversible Bruton's tyrosine kinase (BTK) inhibitor,。The IC₅₀ of Elsubrutinib for BTK catalytic domain is 0.18 μM. Elsubrutinib can be used for the research of inflammatory disease.

研究領域：Protein Tyrosine Kinase/RTK

作用靶點：Btk

In Vitro: Elsubrutinib inhibits BTK (C481S) with an IC₅₀ of 2.6 μM, indicating a significant loss in potency upon exchanging the targeted thiol nucleophile with an alcohol, suggesting Cys481 is important in the manner in which Elsubrutinib inhibits BTK. Elsubrutinib irreversibly inhibits BTK enzyme activity and blocks BTK-dependent cellular activation. Elsubrutinib inhibits histamine release from IgE-stimulated basophils and IL-6 release from IgG-stimulated monocytes, which utilize Fce and Fcc receptors respectively. Elsubrutinib inhibits IgM-mediated B cell proliferation, which is dependent on signaling through the BCR. Elsubrutinib also inhibits TNF-release from CpG-DNA stimulated PBMCs, which signals through TLR9, although it does not inhibit the function of TLRs that do not use ITAM motifs, namely, TNF release from PBMCs stimulated either through TLR4 (with LPS) or through TLR7/8 (with R848). Elsubrutinib has significant impacts on IgM-mediated B cell proliferation.

In Vivo: Elsubrutinib (10 mg/kg; p.o.) inhibits antibody responses to NP-Ficoll and NP-KLH, but not to NP-LPS or Prevnar-13.
Elsubrutinib (0.1~10 mg/kg; p.o.) results in dose-dependent inhibition of paw swelling throughout the course of disease and significantly prevents the onset of proteinuria and prolongs survival at the 10 mg/kg QD and BID doses, while lower doses does not significantly inhibit these endpoints.
Elsubrutinib demonstrates exposure-dependent inhibition of increases in paw volume. Elsubrutinib significantly inhibits bone volume loss in a dose dependent manner consistent with the observed anti-inflammatory effects.

相關產(chǎn)品：Drug Repurposing Compound Library Plus  |  Clinical Compound Library Plus  |  Bioactive Compound Library Plus  |  Immunology/Inflammation Compound Library  |  Kinase Inhibitor Library  |  Protein Tyrosine Kinase Compound Library  |  Clinical Compound Library  |  Drug Repurposing Compound Library  |  Orally Active Compound Library  |  Anti-Blood Cancer Compound Library  |  Heterocyclic Compound Library  |  Membrane Protein-targeted Compound Library  |  Atuzabrutinib  |  PCI 29732  |  JAK3/BTK-IN-6  |  Pirtobrutinib  |  CNX-500  |  BTK inhibitor 17  |  Remibrutinib  |  RN486  |  GDC-0834 Racemate  |  Spebrutinib besylate  |  BTK inhibitor 19  |  BMX-IN-1  |  BMS-935177  |  Ibrutinib  |  PF-06250112  |  QL-X-138  |  SJF620 hydrochloride  |  PROTAC BTK Degrader-2  |  BTK-IN-8  |  JAK3/BTK-IN-3  |  JS25  |  JAK3/BTK-IN-2  |  (R)-Zanubrutinib  |  Edralbrutinib  |  Branebrutinib  |  Poseltinib  |  BTK inhibitor 20  |  RET-IN-14  |  QL47  |  BTK-IN-23

熱門產(chǎn)品線：重組蛋白  |  化合物庫  |  天然產(chǎn)物  |  熒光染料  |  PROTAC  |  同位素標記物  |  寡核苷酸  |  抗體  |  點擊化學

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Fluorescent Dye  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides  |  Antibodies  |  Click Chemistry

品牌介紹:
•   MCE (MedChemExpress) 擁有200 多種*僅有化合物庫，我們致力于為*科研客戶提供前沿的高品質(zhì)小分子活性化合物,；
•   50,000 多種高選擇性抑制劑,、激動劑涉及各熱門信號通路及疾病領；
•   產(chǎn)品種類涵蓋各種重組蛋白,，多肽,，常用試劑盒 ，更有 PROTAC,、ADC 等特色產(chǎn)品,，廣泛應用于新藥研發(fā)、生命科學等科研項目,；
•   提供虛擬篩選,，離子通道篩選，代謝組學分析檢測分析,，藥物篩選等專業(yè)技術服務,；
•   設有專業(yè)的實驗中心和嚴格的質(zhì)控、驗證體系,；
•   提供 LC/MS,、NMR、HPLC,、手性分析,、元素分析等各項質(zhì)檢報告，確保產(chǎn)品的高純度,、高品質(zhì),；
•   產(chǎn)品的生物活性多經(jīng)各國客戶實驗驗證；
•   Nature, Cell, Science 等多種頂級期刊及制藥 Patent 收錄了MCE客戶的科研成果,；
•   專業(yè)團隊跟蹤最新的制藥及生命科學研究進展,，為您提供*新的活性化合物；
•   與世界各大制藥公司及著名科研機構建立了長期的合作,。